查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984152

血液和血漿成分市場：按產品類型、分銷管道、應用和最終用戶分類的全球市場預測 – 2026-2032 年

Blood & Plasma Components Market by Product Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血液和血漿成分市場價值將達到 76 億美元，到 2026 年將成長到 82.1 億美元，到 2032 年將達到 134.1 億美元，年複合成長率為 8.43%。

主要市場統計數據
基準年 2025 76億美元
預計年份：2026年 82.1億美元
預測年份 2032 134.1億美元
複合年成長率 (%) 8.43%

一項著重分析影響醫療保健系統和產業領導者血液和血漿成分管理的臨床、營運和商業性趨勢的分析。

血液和血漿成分領域在現代醫療保健服務中發揮核心作用，是治療通訊協定、診斷流程和生物醫學研究的基礎。本導論概述了影響供應鏈和相關人員決策的關鍵臨床和商業趨勢，整合了成分加工的最新進展、不斷變化的監管環境以及臨床需求的波動模式，為讀者理解後續分析章節奠定了基礎。

技術創新、不斷變化的法規和多元化的供應鏈如何共同重塑整個血液和血漿生態系統的需求趨勢和韌性策略。

該領域正經歷著變革性的轉變，重塑著相關人員管理供應、品質和商業策略的方式。血漿分餾和病原體去除技術的進步提高了產品的安全性和保存期限，而皮下製劑和重組替代物的創新正在重新定義治療應用模式。同時，捐血者互動和庫存管理的數位化正在最佳化血液採集能力，減少廢棄物，並建立更快速的供應網路。這些技術主導的改進與臨床實踐的變革相輔相成，精準醫療和標靶治療正在影響著各類產品的需求結構。

本研究評估了近期關稅調整和貿易政策轉變對血液和血漿來源籌資策略、區域生產決策和供應韌性的影響。

近期關稅措施和貿易政策的發展為血液和血漿成分的採購和分銷策略帶來了新的複雜性。影響進口原料、特殊試劑和血漿衍生成品的關稅調整加劇了供應商和醫療保健系統的成本壓力，迫使採購團隊重新評估其採購區域和供應商合約。為此，許多機構正優先考慮供應鏈透明度和情境規劃，以降低跨境成本波動帶來的風險。

基於詳細的細分，將產品分類、臨床應用、終端用戶行為和分銷管道與市場參與企業的營運重點和商業性策略聯繫起來，從而獲得清晰的見解。

細分市場分析揭示了產品、應用、終端用戶和分銷管道等各個維度上的微妙動態，每個維度都具有其獨特的營運和商業影響。根據產品類型，市場可細分為血漿蛋白、血小板、紅血球和白血球。血漿蛋白本身需要更深入的觀點。白蛋白在體液管理和急救中發揮核心作用。凝血因子，例如因子IX、因子VIII和凝血酶原複合物濃縮液，由於其特定的治療應用和生產要求，需要單獨考慮。免疫球蛋白進一步分為兩種給藥途徑：靜脈注射和皮下注射，每種途徑都有其獨特的給藥和供應需求。

美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、基礎設施成熟度和流通結構如何影響戰略市場進入和業務設計？

區域趨勢對製造商、經銷商和醫療服務提供者的策略選擇有顯著影響。美洲地區擁有先進的加工基礎設施、完善的捐贈項目和成熟的報銷體系，這有利於快速採用先進技術和建立可擴展的分銷網路。相較之下，歐洲、中東和非洲的管理體制各不相同，醫療資金籌措結構不均衡，國內生產能力也存在差異。考慮到這些因素，確保供應的連續性需要對區域樞紐模式和相應的監管策略進行有針對性的投資。

例如，一些主要企業將卓越的製造流程、前瞻性的監管意識和靈活的分銷能力相結合，以確保其整個產品線的臨床可靠性和業務永續營運。

該領域的主要企業正在展現出能力融合的趨勢，將先進的製造流程、一體化的品管和策略性經銷夥伴相結合。投資於尖端分餾和病原體減少技術的企業正在贏得監管機構和臨床機構的信任，而那些優先考慮供應鏈透明度和數位化庫存管理的企業則在減少廢棄物並提高分銷準確性。製造商與醫院網路之間的策略夥伴關係有助於需求預測和庫存管理，從而實現更快的補貨速度並減少對臨床環境的干擾。

為經營團隊提供切實可行的策略建議，以加強生產安全、實現供應鏈多元化、提升數位化和監管能力，從而增強永續的韌性。

產業領導者應採取積極主動的策略，整合技術投資、策略夥伴關係以及提升業務永續營運的措施，以應對當前複雜的情況。首先，加速採用先進的加工和病原體減少技術將提高產品安全性，減少廢棄物，從而增強臨床和監管機構的信心。同時，投資於端到端的數位化視覺性，涵蓋從捐贈者招募分析到庫存和低溫運輸監控的各個環節，將有助於更準確地預測需求，並更快地應對供應中斷。

透明且可重複的研究途徑，結合專家訪談、監管和臨床文獻審查以及情境分析，確保了可操作性和檢驗的研究結果。

本調查方法結合了多方面的質性分析、相關人員訪談和結構化的二手研究，旨在建構嚴謹且可重複的證據基礎。其中一項關鍵工作是與臨床負責人、採購負責人、供應鏈經理和監管專家進行專家訪談，以了解實際限制和策略重點。從這些對話中獲得的見解構成了主題分析的基礎，並有助於檢驗關於產品使用模式和分銷管道趨勢的假設。

它從策略上整合了臨床、營運和商業性影響，突顯了整個產業進行協作現代化和增強韌性工作的迫切性。

結論部分總結了報告對臨床、商業和營運相關人員的核心啟示。血液和血漿製品產業正處於戰略轉折點，技術創新、監管變革和供應鏈重組在此交匯，重新定義了韌性和可及性的概念。優先投資於更安全的加工技術、強大的數位可視性和多元化的供應鏈網路的機構，將更有能力抵禦衝擊，並保障依賴這些關鍵治療方法的患者的持續治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血液和血漿成分市場：按產品類型分類

  • 電漿番茄
    • 白蛋白
    • 凝血因子
    • 免疫球蛋白
      • 靜脈注射免疫球蛋白
      • 皮下注射免疫球蛋白
  • 血小板
  • 紅血球
  • 白血球

第9章 血液和血漿成分市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 血液與血漿成分市場：依應用分類

  • 診斷
  • 研究
  • 治療

第11章 血液和血漿成分市場：按最終用戶分類

  • 診斷檢查室
  • 醫院
    • 門診手術中心
    • 公立醫院
    • 私立醫院
  • 研究機構

第12章 血液和血漿成分市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血液與血漿成分市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血液與血漿成分市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血液與血漿成分市場

第16章 中國血液與血漿成分市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adma Biologics, Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Bio Products Laboratory Limited
  • BioLife Plasma Services LP
  • Biotest AG
  • Cerus Corporation
  • CSL Limited
  • Fapon Biotech Inc.
  • Fresenius SE & Co. KGaA
  • Grifols, SA
  • Haemonetics Corporation
  • Immucor, Inc.
  • Johnson & Johnson Services, Inc.
  • KEDRION SpA
  • LFB SA
  • Macopharma SAS
  • Medline Industries, LP
  • Octapharma AG
  • Quotient Limited
  • Sanquin Blood Supply Foundation
  • Shanghai RAAS Blood Products Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • Terumo Corporation
Product Code: MRR-5C6F41F5AF8E

The Blood & Plasma Components Market was valued at USD 7.60 billion in 2025 and is projected to grow to USD 8.21 billion in 2026, with a CAGR of 8.43%, reaching USD 13.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.60 billion
Estimated Year [2026] USD 8.21 billion
Forecast Year [2032] USD 13.41 billion
CAGR (%) 8.43%

A focused orientation to the clinical, operational, and commercial dynamics shaping blood and plasma component management for health systems and industry leaders

The blood and plasma components landscape occupies a central role in modern healthcare delivery, underpinning therapeutic protocols, diagnostic workflows, and biomedical research. This introduction frames the core clinical and commercial contours that influence supply chains and stakeholder decision-making. It synthesizes recent advances in component processing, the evolving regulatory environment, and shifting patterns of clinical demand, establishing a foundation for readers to interpret subsequent analytical chapters.

Clinicians and procurement leaders face a complex interplay of clinical need and supply chain constraints. On one hand, therapeutic reliance on plasma proteins such as immunoglobulins and coagulation factors remains high across diverse indications. On the other hand, operational pressures-ranging from donor recruitment and collection logistics to cold-chain management and distribution channel transformations-require integrated responses across institutions. By framing the primary vectors of change, this introduction prepares leaders to evaluate risk, prioritize resilience measures, and align investment with clinical imperatives.

The section closes by articulating the analytical approach used throughout the report: a focus on product-specific dynamics, application-driven utilization patterns, end-user operational realities, and distribution channel effectiveness. This orientation equips readers to follow the subsequent deep-dive analyses with clarity and to translate insights into tactical and strategic actions that enhance patient care and institutional robustness.

How technological innovation, regulatory evolution, and supply chain diversification are jointly reshaping demand profiles and resilience strategies across the blood and plasma ecosystem

The sector is experiencing transformative shifts that recalibrate how stakeholders manage supply, quality, and commercial strategy. Technological advances in plasma fractionation and pathogen reduction have improved product safety and shelf life, while innovations in subcutaneous delivery formats and recombinant alternatives are reshaping therapeutic use patterns. Concurrently, digitalization of donor engagement and inventory management is optimizing collection throughput and reducing waste, enabling more responsive supply networks. These technology-driven improvements are complemented by changes in clinical practice, where precision medicine and targeted therapeutics are influencing demand composition across product classes.

Policy and regulatory evolution also drives transformation. Regulators are deploying more rigorous pharmacovigilance expectations and novel guidance on plasma-derived products that demand closer lifecycle oversight from manufacturers and distributors. Moreover, geopolitical tensions and trade policy adjustments have increased the emphasis on regional self-reliance and diversified sourcing, prompting firms and health systems to reconsider single-supplier dependencies. As a result, commercial models are shifting toward strategic partnerships, domestic capacity expansion, and flexible distribution agreements that can withstand policy shocks.

Taken together, these shifts create an environment in which agility, technological adoption, and regulatory foresight become critical differentiators. Organizations that invest in integrated supply chain visibility, adopt safer and more efficient processing technologies, and proactively engage with evolving regulatory frameworks will be better positioned to meet clinical demand while maintaining cost-effectiveness and quality standards.

Assessing how recent tariff realignments and trade policy shifts are reconfiguring procurement strategies, regional production decisions, and supply resilience for blood and plasma inputs

Recent tariff measures and trade policy developments have introduced new layers of complexity into procurement and distribution strategies for blood and plasma components. Tariff adjustments affecting imported raw materials, specialized reagents, and finished plasma-derived products have increased cost pressure for suppliers and health systems, compelling procurement teams to reassess sourcing geographies and supplier agreements. In response, many organizations have prioritized supply chain transparency and scenario planning to mitigate exposure to cross-border cost volatility.

Beyond direct cost impacts, tariff shifts influence strategic behaviors among manufacturers and distributors. Some producers have accelerated regionalization of production and established additional processing hubs to circumvent tariff-related frictions and to maintain access to key markets. Distributors, in turn, have diversified inventory holdings and renegotiated contractual terms with health systems to share risk and preserve continuity of care. These adaptations often involve longer-term commercial commitments and investments in local cold-chain infrastructure, which can stabilize supply but may also raise capital intensity.

Clinicians and hospital operations teams feel the downstream effects in procurement cycles and inventory policies. Planning horizons have lengthened as stakeholders incorporate potential tariff disruptions into stocking and substitution decisions, and collaboration across procurement, clinical, and regulatory teams has become essential to maintain treatment pathways. Ultimately, the evolving tariff landscape underscores the need for multi-layered resilience strategies that combine local capacity building, flexible distribution models, and proactive regulatory engagement to safeguard patient access and clinical continuity.

Deep segmentation-driven clarity that links product classes, clinical applications, end-user behaviors, and distribution channels to operational priorities and commercial tactics for market participants

Segmentation analysis reveals nuanced dynamics across product, application, end-user, and distribution channel dimensions, each of which drives distinct operational and commercial implications. Based on product type, the market differentiates between plasma proteins, platelets, red blood cells, and white blood cells. Plasma proteins themselves require a deeper lens: albumin plays a central role in volume and critical care management; coagulation factors must be examined across Factor IX, Factor VIII, and prothrombin complex concentrates due to their specific therapeutic applications and manufacturing considerations; and immunoglobulins are split into intravenous and subcutaneous modalities, each with unique administration and supply requirements.

Based on application, diagnostic, research, and therapeutic uses produce divergent demand rhythms and regulatory expectations. Diagnostic consumption emphasizes consistent availability for laboratory workflows and reagent quality, research demand fluctuates with grant cycles and clinical trial activity, and therapeutic utilization follows clinical practice patterns and treatment protocol adoption. Based on end user, diagnostic laboratories, hospitals, and research institutions impose different procurement constraints and service expectations. Within hospitals, the spectrum includes ambulatory surgical centers, government hospitals, and private hospitals, each exhibiting distinct purchasing power, inventory practices, and clinical pathway integration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies vary in their fulfillment models, regulatory compliance requirements, and patient access touchpoints, affecting how products are delivered and managed at the point of care.

These segmentation lenses intersect to create complex value chains. For example, immunoglobulin demand in private hospitals delivered via hospital pharmacies requires different contracting and logistic arrangements than immunoglobulin for research supplied through online pharmacy channels. Recognizing these intersections enables more precise prioritization of investments in cold-chain capacity, formulation innovation, and channel-specific commercial tactics that align product attributes with end-user needs and distribution realities.

How regional regulatory diversity, infrastructure maturity, and distribution architectures across the Americas, Europe Middle East & Africa, and Asia-Pacific shape strategic market entry and operational design

Regional dynamics significantly condition strategic options for manufacturers, distributors, and healthcare providers. The Americas show a concentrated blend of advanced processing infrastructure, well-established donor programs, and mature reimbursement frameworks that favor rapid adoption of technological improvements and scalable distribution networks. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes, heterogeneous healthcare financing arrangements, and varying levels of domestic manufacturing capability, which together demand tailored regulatory strategies and selective investments in regional hub models to ensure supply continuity.

Asia-Pacific demonstrates rapid growth in healthcare infrastructure investment, expansion of domestic plasma collection capacity, and a rising emphasis on localized manufacturing to meet growing clinical demand. Within each region, differences in procurement sophistication, regulatory stringency, and distribution channel maturity influence how organizations design supply strategies and commercial partnerships. For instance, markets with advanced hospital pharmacy networks can deploy centralized inventory optimization tools, whereas regions with diverse retail and online channels may require omnichannel distribution strategies and enhanced cold-chain monitoring.

Taken together, regional insights underscore the importance of differentiated market entry approaches and adaptive operational models. Firms that calibrate their commercial propositions to regional regulatory landscapes, payer mechanisms, and distribution architectures will more effectively balance access, quality, and cost considerations across global footprints.

Profiles of industry players that combine manufacturing excellence, regulatory foresight, and distribution agility to secure clinical trust and operational resilience across product lines

Leading organizations within the sector demonstrate a convergence of capabilities that combine advanced manufacturing, integrated quality management, and strategic distribution partnerships. Companies that invest in modern fractionation and pathogen mitigation technologies secure both regulatory confidence and clinical trust, while those that emphasize supply chain transparency and digital inventory controls reduce waste and improve allocation precision. Strategic alliances between manufacturers and hospital networks facilitate demand forecasting and buffer management, enabling more responsive replenishment and reduced clinical disruption.

Competitive differentiation increasingly arises from portfolio breadth and modality flexibility. Firms offering varied formulations-such as both intravenous and subcutaneous immunoglobulins-and a portfolio that spans albumin and targeted coagulation factors, can better meet heterogeneous clinical needs. Additionally, companies that develop multi-channel distribution models, incorporating hospital pharmacies, online fulfillment, and retail partnerships, create more resilient access pathways for patients and providers. Effective companies also engage regulators proactively, collaborating on post-market surveillance and safety reporting to maintain product integrity and market trust.

Ultimately, the organizations that perform best combine technical excellence in processing with commercial agility and an ability to partner across the ecosystem. Their capabilities in manufacturing, regulatory navigation, and distribution orchestration position them to respond to shifting clinical protocols and supply chain pressures while maintaining patient safety.

Practical and strategic recommendations for executive teams to strengthen manufacturing safety, diversify supply networks, and enhance digital and regulatory capabilities for enduring resilience

Industry leaders should adopt a proactive stance that integrates technological investment, strategic partnerships, and operational resilience measures to navigate current complexities. First, accelerating deployment of advanced processing and pathogen-reduction technologies will improve product safety and reduce wastage, thereby strengthening clinical and regulatory confidence. Concurrently, investing in end-to-end digital visibility-from donor recruitment analytics through inventory and cold-chain monitoring-will enable more accurate demand forecasting and rapid response to supply disruptions.

Second, leaders must cultivate diversified supply strategies that blend regional production capacity, multi-supplier agreements, and flexible distribution arrangements tailored to hospital pharmacies, online fulfillment, and retail channels. These strategies should be coupled with contractual terms that share risk and incentivize service continuity. Third, proactive regulatory engagement is essential: companies and healthcare institutions should invest in dedicated regulatory intelligence and pharmacovigilance capabilities to anticipate policy shifts and to respond efficiently to safety queries.

Finally, close collaboration between manufacturers, clinical leaders, and procurement teams will translate strategic intent into operational reality. Joint scenario planning, shared KPIs for supply reliability, and periodic cross-functional reviews will align incentives and reduce the risk of treatment interruption. By implementing these measures, industry leaders can enhance patient access while managing cost and compliance imperatives.

A transparent and reproducible research approach combining expert interviews, regulatory and clinical literature review, and scenario analysis to ensure actionable and validated insights

The research methodology combines multi-source qualitative analysis, stakeholder interviews, and structured secondary research to build a rigorous and reproducible evidence base. Primary engagement included expert interviews with clinical leaders, procurement officers, supply chain managers, and regulatory specialists to capture real-world operational constraints and strategic priorities. These conversations informed thematic analyses and validated assumptions about product utilization patterns and channel behaviors.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical guidelines to triangulate findings and ensure alignment with current practice standards. The analytic process emphasized cross-validation: insights derived from interviews were compared against documented regulatory developments and clinical practice trends to reduce bias. In addition, scenario analyses were used to explore the implications of supply disruptions, trade policy shifts, and technology adoption, enabling robust recommendations that reflect plausible operational futures.

Throughout the methodology, emphasis was placed on transparency, reproducibility, and practical relevance. The result is a structured framework that links evidence to conclusions and that supports decision-makers in translating insights into targeted actions across procurement, clinical operations, and commercial strategy.

Strategic synthesis of clinical, operational, and commercial implications that underscores the urgency of coordinated modernization and resilience initiatives across the sector

The conclusion synthesizes the report's core implications for clinical, commercial, and operational stakeholders. The blood and plasma components arena is at a strategic inflection point where technological innovation, regulatory change, and supply chain reconfiguration intersect to redefine resilience and access. Organizations that prioritize investment in safer processing technologies, robust digital visibility, and diversified supply networks will be better equipped to absorb shocks and to maintain continuity of care for patients reliant on these critical therapies.

Moreover, the interplay of product segmentation, application-specific demand, and distribution channel dynamics requires coordinated cross-functional strategies. Procurement leaders, clinical directors, and manufacturing executives must align incentives and share real-time information to prevent shortages, optimize inventory, and support evidence-driven substitution where clinically appropriate. Regional strategies should reflect local regulatory regimes and distribution architectures, while commercial approaches must maintain flexibility to accommodate differing end-user needs.

In closing, success in this sector depends on marrying technical excellence with strategic adaptability. Stakeholders that act decisively to modernize operations, engage regulators proactively, and form resilient partnerships will secure both clinical reliability and competitive advantage in a dynamic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood & Plasma Components Market, by Product Type

  • 8.1. Plasma Proteins
    • 8.1.1. Albumin
    • 8.1.2. Coagulation Factors
    • 8.1.3. Immunoglobulins
      • 8.1.3.1. Intravenous Immunoglobulin
      • 8.1.3.2. Subcutaneous Immunoglobulin
  • 8.2. Platelets
  • 8.3. Red Blood Cells
  • 8.4. White Blood Cells

9. Blood & Plasma Components Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Blood & Plasma Components Market, by Application

  • 10.1. Diagnostic
  • 10.2. Research
  • 10.3. Therapeutic

11. Blood & Plasma Components Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Ambulatory Surgical Centers
    • 11.2.2. Government Hospitals
    • 11.2.3. Private Hospitals
  • 11.3. Research Institutions

12. Blood & Plasma Components Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood & Plasma Components Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood & Plasma Components Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blood & Plasma Components Market

16. China Blood & Plasma Components Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adma Biologics, Inc.
  • 17.6. Baxter International Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio Products Laboratory Limited
  • 17.9. BioLife Plasma Services L.P.
  • 17.10. Biotest AG
  • 17.11. Cerus Corporation
  • 17.12. CSL Limited
  • 17.13. Fapon Biotech Inc.
  • 17.14. Fresenius SE & Co. KGaA
  • 17.15. Grifols, S.A.
  • 17.16. Haemonetics Corporation
  • 17.17. Immucor, Inc.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. KEDRION S.p.A.
  • 17.20. LFB S.A.
  • 17.21. Macopharma S.A.S.
  • 17.22. Medline Industries, LP
  • 17.23. Octapharma AG
  • 17.24. Quotient Limited
  • 17.25. Sanquin Blood Supply Foundation
  • 17.26. Shanghai RAAS Blood Products Co., Ltd
  • 17.27. Takeda Pharmaceutical Company Limited
  • 17.28. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)